Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders
Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani’s lead program, AM-01.
